Participated · Equity · Feb 2024

DeepLook Medical’s flagship product, DL Precise™, is an AI-powered software that uses shape-recognition algorithms to visualize, measure, and segment abnormal growths in dense breast tissue. The company positions DL Precise™ as a tool to improve accuracy in detecting and assessing suspicious lesions, with the potential to enhance early cancer detection and patient outcomes. DeepLook says its technology is the first in a series of products built on its unique shape-recognition software and leveraged alongside complementary AI advances and patented technology. The company plans to use newly raised capital to further commercialize its technology with current and new partners, explore applications in additional imaging modalities, and broaden its global presence. DeepLook emphasizes improving physician diagnosis and treatment decisions across oncology through clearer tumor morphology delineation. The press release highlights Xcellerant’s support and strategic involvement as part of its commercialization efforts. DeepLook Medical, led by CEO Marissa Fayer and based in New Haven, Connecticut, develops AI software to improve visualization of suspicious masses in dense breasts. Its flagship product, DL Precise, is an FDA-cleared shape-recognition platform that overlays onto existing imaging screens to provide one-click measurement, segmentation, and visualization. DL Precise delineates tumor morphology using a single-click deterministic algorithm and is compatible with mammography, ultrasound, CT, and MRI. The product has entered the commercial market through partnerships with Barco, Blackford, Tempus, and Radical Imaging. DeepLook plans to use the $1.7M funding to hire talent, advance next-generation products, expand sales and partnerships, support additional clinical research and publications, and extend global IP and regulatory protections and clearances. The company is also leveraging complementary AI advances to enhance the reach and impact of its patented technology.

Led · Series A · Nov 2022

Torigen Pharmaceutical is a commercial-stage animal health biologics company that aims to innovate pet cancer treatment by leveraging the pet’s immune system to create personalized cancer immunotherapies. Led by CEO Ashley Kalinauskas, the company is a spin-out from the University of Notre Dame and is based in Farmington, CT. Torigen is focused on developing new biologic products to treat cancer in companion animals. The company says it will use the proceeds from its latest financing to continue to develop new products and expand its salesforce. The company is described as commercial-stage. The recent financing provides additional capital to support its product development and commercial expansion.

Participated · Series B · Jul 2021

MedRhythms’ core product is a digital therapy platform that combines sensors, music and software to deliver an evidence‑based intervention called rhythmic auditory stimulation to improve gait after neurologic injury. The platform leverages musical entrainment to engage auditory‑motor brain circuitry and promote neuroplasticity. Its lead digital therapeutic received Breakthrough Device designation from the U.S. FDA to treat chronic walking deficits from stroke. The company is preparing an FDA submission to enable a commercial launch and plans to begin clinical trials. MedRhythms is also expanding its treatment pipeline to explore music‑based therapies for Parkinson’s, acute stroke and multiple sclerosis and is participating in a neuroimaging study with Massachusetts General Hospital. Financially, the company has raised $31 million to date following the recent Series B. MedRhythms develops a patent-pending digital therapeutics platform that combines sensors, AI, and music to deliver evidence-based, prescription products aimed at improving and measuring walking in people with neurologic injuries and diseases. The company’s first product targets the post-stroke population, and its pipeline includes therapies for Parkinson’s Disease, Multiple Sclerosis, Aging‑In‑Place, and Traumatic Brain Injury. MedRhythms intends to pursue FDA approval for its prescription digital therapeutics and to build algorithms for personalized therapeutics addressing movement, language, and cognition deficits. The platform also collects data the company says can be used for early disease detection, tracking progression, and predicting adverse events. Following the financing, MedRhythms plans to hire software, product, and commercial staff for its Portland, ME office. The company began as a therapy services business that launched out of Spaulding Rehabilitation Hospital.

Led · Series A · Aug 2017

Likarda is a regenerative medicine company advancing a proprietary diabetes treatment for dogs and cats. Founded in 2012 by Lisa Stehno-Bittel, the Kansas City, Kansas–based lab is developing insulin-producing cell clusters called the Kanslet™, which are microencapsulated islets that can be infused into animals. The microencapsulated islets are transplanted via injection into the belly of a diabetic dog, aiming to remove the need for twice-daily insulin injections. After years of development and work with partners, Likarda is in the process of bringing islet transplants to dogs. The company raised $4M in a Series A and intends to use the funds to scale the program from treating hundreds of animals to thousands. Its clinical research program was being finalized and expected to launch by the end of 2017.